netFormulary
 Report : Medicines with links to NICE 25/02/2020 11:11:40

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Abatacept 10.01.03 Formulary NICE TA195 August 2010: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Abatacept 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abatacept 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abiraterone 08.03.04.02 Formulary NICE TA259: Abiraterone for castration resistant prostate cancer
Abiraterone 08.03.04.02 Formulary NICE TA387:Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Acetylcysteine 03.11 Formulary NICE CG163 May 17 update: Idiopathic pulmonary fibrosis in adults: diagnosis and management
Adalimumab 13.05.03 Formulary NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab 13.05.03 Formulary NICE TA146 Adalimumab for the treatment of adults with psoriasis
Adalimumab 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Adalimumab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Adalimumab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Adalimumab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Adalimumab 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Adalimumab 01.05.03 Formulary NICE TA187: Crohn’s disease - infliximab and adalimumab
Adalimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Adefovir Dipivoxil 05.03.03.01 Formulary NICE TA96: Hep B - adefovir dipivoxil and pegylated interferon alpha-2a
Adefovir Dipivoxil 05.03.03.01 Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA96
Adrenaline / epinephrine 03.04.03 Formulary NICE CG134: Anaphylaxis: Assessment and referral after emergency treatment
Afatinib 08.01.05 Formulary NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Aflibercept 08.01.05 Non Formulary NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Aflibercept 11.08.02 Formulary NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Aflibercept 11.08.02 Formulary NICE TA346: Aflibercept for treating diabetic macular oedema
Aflibercept 11.08.02 Formulary NICE TA294: Aflibercept solution for injection for treating wet age‑related macular degeneration
Aflibercept 11.08.02 Formulary NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Alectinib 08.01.05 Non Formulary NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
Alemtuzumab 08.02.03 Formulary NICE TA312: Alemtuzumab for relapsing‑remitting multiple sclerosis
Alirocumab 02.12 Formulary NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin 13.05.01 Formulary NICE TA177 Alitretinoin for the treatment of severe chronic hand eczema Aug 2009
Alteplase 02.10.02 Formulary NICE TA264: Ischaemic stroke (acute) - alteplase
Anti-D (Rh0) Immunoglobulin 14.05.03 Formulary NICE TA156: Anti-D in pregnant women
Anti-D (Rh0) Immunoglobulin 14.05 Formulary NICE TA156 (Aug 2008) - Routine antenatal anti-D prophylaxis for women who are rhesus D negative
Apixaban 02.08.02 Formulary NICE TA275: Apixaban for AF
Apixaban 02.08.02 Formulary NICE TA341 June 2015: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Apixaban 02.08.02 Formulary NICE TA245 Jan 2012: Apixaban for the prevention of venous thromboembolism after total hip or knee replacement in adults
Apremilast 10.01.03 Formulary NICE TA433 Apremilast for treating active psoriatic arthritis Feb 2017
Apremilast 13.05.03 Formulary NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
Apremilast 13.05.03 Formulary NICE TA433 : Apremilast for treating active psoriatic arthritis
Aquacel Extra A5.02.04 Non Formulary NICE TA448 : Etelcalcetide for treating secondary hyperparathyroidism
Aquacel Extra A5.02.04 Non Formulary NICE TA456: Baricitinib for moderate to severe rheumatoid arthritis
Aquacel Extra A5.02.04 Non Formulary NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
Aripiprazole 04.02.01 Formulary NICE TA292: Bipolar disorder (children) - aripiprazole
Aripiprazole 04.02.01 Formulary NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years
Arsenic Trioxide 08.01.05 Formulary NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
Atezolizumab 08.01.05 Formulary NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Atezolizumab 08.01.05 Formulary NICE TA520 : Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Atezolizumab 08.01.05 Formulary NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Atomoxetine 16.05 Formulary NICE NG87 Attention deficit hyperactivity disorder: diagnosis and management Sept 2019
Atorvastatin 02.12 Formulary NICE CG181 Sept 2016: Cardiovascular disease: risk assessment and reduction, including lipid modification
Avelumab 08.01.05 Non Formulary NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
Axitinib 08.01.05 Formulary NICE TA333: Axitinib for advanced renal cell carcinoma
Azacitidine 08.01.03 Formulary NICE TA218: azacitidine for myelodysplastic syndromes
Baricitinib 10.01.03 Formulary NICE TA466 August 2017: Baricitinib for moderate to severe rheumatoid arthritis
Basiliximab 08.02.02 Non Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Basiliximab 08.02.02 Non Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Belimumab 10.01.03 Formulary NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Bendamustine 08.01.01 Formulary NICE TA216: Bendamustine for CLL
Bevacizumab 08.01.05 Non Formulary NICE TA263: Breast cancer with capecitabine
Bevacizumab 08.01.05 Non Formulary NICE TA214: Breast Cancer with taxane
Bevacizumab 08.01.05 Non Formulary NICE TA285: Ovarian, fallopian tube and primary peritoneal cancer (recurrent advanced, platinum-sensitive or partially platinum-sensitive) - bevacizumab
Bezafibrate 02.12 Formulary NICE: Do Not Do Recommendation
Bismuth subsalicylate 01.03.03 Formulary NICE Pathway: Helicobacter pylori testing and eradication in adults
Bisphosphonates 09.05.01.02 Non Formulary NICE TA464 : Bisphosphonates for treating osteoporos
Bivalirudin 02.08.01 Formulary NICE TA230 : Bivalirudin for the treatment of STEMI, 2011
Blinatumomab 08.02 Formulary NICE TA450 : Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Bortezomib 08.01.05 Formulary NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Bortezomib 08.01.05 Formulary NICE TA228: 1st line treatment of multiple myeloma
Bortezomib 08.01.05 Formulary NICE TA311: Bortezomib for induction therapy in multiple myeloma
Bortezomib 08.01.05 Formulary NICE TA129: Multiple myeloma - bortezomib
Bosutinib 08.01.05 Formulary NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
Botulinum A toxin 04.09.03 Formulary NICE TA260 Botulinum toxin type A for the prevention of headaches in adults with chronic migraine June 2012
Botulinum A toxin 04.09.03 Formulary NICE TA605 Xeomin (botulinum neurotoxin type A) for treating chronic sialorrhoea October 2019
Botulinum A toxin 04.07.04.02 Formulary NICE TA 260 Botulinum toxin type A for the prevention of headaches in adults with chronic migraine June 2012
Botulinum toxin 07.04.03 Formulary NICE NG123 June 2019: Urinary incontinence and pelvic organ prolapse in women: management
Brentuximab 08.01.05 Formulary NICE TA577 Brentuximab vedotin for treating CD30-positive cutaneous T-cell lymphoma
Brentuximab 08.01.05 Formulary NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brentuximab 08.01.05 Formulary NICE TA478L Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Brigatinib 08.01.05 Formulary NICE TA571 :Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib
Brodalumab 13.05 Formulary NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis
Brodalumab 13.05.03 Formulary NICE TA511 Brodalumab for treating moderate to severe plaque psoriasis March 2018
Cabazitaxel 08.01.05 Formulary NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cabozantinib 08.01.05 Formulary NICE TA463 : Cabozantinib for previously treated advanced renal cell carcinoma
Cabozantinib 08.01.05 Formulary NICE TA516: Cabozantinib for treating medullary thyroid cancer
Cabozantinib 08.01.05 Formulary NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
Cabozantinib 08.01.05 Formulary NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
Canagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Canagliflozin 06.01.02.03 Formulary NICE TA315: Canagliflozin for type 2 diabetes
Canagliflozin 06.01.02.03 Formulary NICE TA315 June 2014: Canagliflozin in combination therapy for treating type 2 diabetes
Cangrelor 02.09 Non Formulary NICE TA351: Reducing Artherothrombotic Events
Capecitabine 08.01.03 Formulary NICE TA191: Gastric cancer (advanced) - capecitabine
Capecitabine 08.01.03 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Carfilzomib 08.01.05 Formulary NICE TA457 : Carfilzomib for previously treated multiple myeloma
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Carmustine 08.01.01 Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Cenegermin 11.04 Non Formulary NICE TA532: Cenegermin for treating neurotrophic keratitis
Ceritinib 08.01.05 Formulary NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Ceritinib 08.01.05 Formulary NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
Certolizumab 200mg 13.05.03 Formulary NICE TA574 Certolizumab pegol for treating moderate to severe plaque psoriasis April 2019
Certolizumab Pegol 10.01.03 Formulary NICE TA445 : Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARD
Certolizumab Pegol 10.01.03 Formulary NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Certolizumab Pegol 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Certolizumab Pegol 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Cetuximab 08.01.05 Formulary NICE TA145: Head and neck cancer - cetuximab
Cetuximab 08.01.05 Formulary NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
Cetuximab 08.01.05 Formulary NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Ciclosporin 11.99.99.99 Non Formulary NICE TA369 - Ciclosporin for treating eye disease that has not improved despite treatment with artificial tears
Ciclosporin 11.08.01 Formulary NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Ciclosporin 11.08.01 Formulary NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Ciclosporin 16.15 Formulary NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Cinacalcet 09.05.01.02 Formulary NICE TA117 Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy
Clearfilm A5.02.02 Non Formulary NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea
Clomifene Citrate 06.05.01 Formulary NICE CG156 Sept 2017: Fertility problems: assessment and treatment
Cobimetinib 08.02.04 Non Formulary NICE TA414: Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma
Colecalciferol 800 units 09.06.04 Non Formulary NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
Colistimethate 05.01.07 Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Collagenase 10.03.01 Formulary NICE TA459 : Collagenase clostridium histolyticum for treating Dupuytren’s contracture
Conjugated oestrogens + Bazedoxifene 06.04.01.01 Non Formulary NICE TA443 : Obeticholic acid for treating primary biliary cholangitis
Crizotinib 08.01.05 Formulary NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib 08.01.05 Formulary NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cance
Dabigatran 02.08.02 Formulary NICE TA327 Dec 2014: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
Dabigatran 02.08.02 Formulary NICE TA249: Dabigatran for Stroke prevention in AF
Dabigatran 02.08.02 Formulary NICE TA157 Sept 2008: Dabigatran etexilate for the prevention of venous thromboembolism after hip or knee replacement surgery in adults
Dabrafenib 08.01.05 Formulary NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanom
Dabrafenib 08.01.05 Formulary NICE TA321:Dabrafenib for BRAF V600 +ve melanoma
Dabrafenib 08.01.05 Formulary NICE TA396:Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Daclatasvir 05.03.03.02 Formulary NICE TA364: Daclatasvir for treating chronic hepatitis C
Daclizumab 08.02.02 Non Formulary NICE TA441 : Daclizumab for treating relapsing–remitting multiple sclerosis
Dapagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA288 November 2016: Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA418 November 2016 Dapagliflozin in triple therapy for treating type 2 diabetes
Dapagliflozin 06.01.02.03 Formulary NICE TA597 August 2019: Dapagliflozin with insulin for treating type 1 diabetes
Darbepoetin Alfa 09.01.03 Formulary NICE NG8 June 2015: Chronic kidney disease: managing anaemia
Darbepoetin Alfa 09.01.03 Formulary NICE TA323 Nov 2014: Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy
Dasabuvir 05.03.03.02 Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Dasatinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Dasatinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Decitabine 08.01.03 Non Formulary NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal)
Defibrotide 08.01.05 Restricted Use Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
Degarelix 08.03.04.02 Formulary NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab 06.06.02 Formulary NICE TA 265: Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Denosumab 06.06.02 Formulary NICE TA265: Bone metastases from solid tumours - denosumab: guidance
Denosumab 06.06.02 Formulary NICE TA204: Osteoporotic fractures - denosumab
Desmopressin 06.05.02 Formulary NICE CG111 Oct 2010: Bedwetting in under 19s
Dexamethasone 11.04.01 Formulary NICE TA349: Diabetic Macular Oedema
Dexamfetamine Sulphate 16.05 Formulary NICE NG87 Attention deficit hyperactivity disorder: diagnosis and management Sept 2019
Dimethyl fumarate 08.02.04 Formulary NICE TA320: Dimethyl fumarate for multiple sclerosis
Dinutuximab 08.02.04 Formulary NICE TA538: Dinutuximab beta for treating neuroblastoma
Docetaxel 08.01.05 Formulary NICE TA109: Breast cancer (early) - docetaxel
Docetaxel 08.01.05 Formulary NICE TA101: Prostate cancer (hormone-refractory) - docetaxel
Doxorubicin 08.01.02 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Dronedarone 02.03.02 Formulary NICE TA197: Atrial fibrillation - dronedarone
Dupilumab 13.05.03 Formulary NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis
Edoxaban 02.08.02 Formulary NICE TA355:Edoxaban for preventing stroke/systemic embolism in non‑valvular atrial fibrillation
Edoxaban 02.08.02 Formulary NICE TA354 Aug 2015: Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism
Elosulfase alfa 09.08.01 Non Formulary NICE HST2 Guidance for treating mucopolysaccaridosis
Elosulfase alfa 09.08.01 Non Formulary NICE Managed Access Agreement Elosulfase alfa for treating mucopolysaccharidosis type IVa
Eltrombopag 09.01.04 Formulary NICE TA293: Eltrombopag for treating chronic ITP
Empagliflozin 06.01.02.03 Formulary NICE TA336: Empagliflozin for type 2 diabetes
Empagliflozin 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Empagliflozin 06.01.02.03 Formulary NICE TA336 March 2015: Empagliflozin in combination therapy for treating type 2 diabetes
Emtricitabine + rilpivirine + tenofovir alafenamide 05.03.01 Non Formulary NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
Entecavir 05.03.03.01 Formulary NICE CG165: Hepatitis B (incorporates TA153)
Entecavir 05.03.03.01 Formulary NICE TA153: Hepatitis B (chronic) - etecavir
Enzalutamide 08.03.04.02 Formulary NICE TA316: Enzalutamide for prostate cancer
Enzalutamide 08.03.04.02 Formulary NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Eplerenone 02.02.03 Formulary NICE CG108: Chronic heart failure
Epoetin alfa 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Epoetin alfa 09.01.03 Formulary NICE NG8 June 2015: Chronic kidney disease: managing anaemia
Epoetin beta 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Epoetin beta 09.01.03 Formulary NICE NG8 June 2015: Chronic kidney disease: managing anaemia
Eribulin 08.01.05 Formulary NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Erlotinib 08.01.05 Formulary NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Erlotinib 08.01.05 Formulary NICE TA258: Lung cancer (non-small-cell) 1st line- erlotinib
Erlotinib 08.01.05 Formulary NICE TA227: Lung cancer (non-small-cell) maintenance - erlotinib
Ertugliflozin 06.01.02.03 Formulary NICE TA572 March 2019: Ertugliflozin as monotherapy or with metformin for treating type 2 diabetes
Ertugliflozin 06.01.02.03 Formulary NICE TA 583 - Ertugliflozin with metformin and a dipeptidyl peptidase-4 inhibitor for treating type 2 diabetes
Esomeprazole 01.03.05 Formulary NICE Pathway: Helicobacter pylori testing and eradication in adults
Etanercept 10.01.03 Non Formulary NICE TA455 : Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Etanercept 10.01.03 Non Formulary NICE TA199: Psoriatic arthritis
Etanercept 10.01.03 Non Formulary NICE TA35: Adult psoriasis
Etanercept 10.01.03 Non Formulary NICE TA195: Rheumatoid arthritis after the failure of a TNF inhibitor
Etanercept 10.01.03 Non Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Non Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 10.01.03 Non Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for JIA
Etanercept 13.05.03 Formulary NICE TA103: Psoriasis - efalizumab and etanercept
Etanercept 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Etanercept 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept 10.01.03 Formulary NICE TA195: rheumatoid arthritis after the failure of a TNF inhibitor
Etelcalcetide 09.05.01.02 Formulary NICE TA448 June 2017: Etelcalcetide for treating secondary hyperparathyroidism
Everolimus 08.01.05 Formulary NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Everolimus 08.01.05 Formulary NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Everolimus 08.01.05 Formulary NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Everolimus 08.01.05 Formulary NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Evolocumab 02.12 Formulary NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Ezetimibe 02.12 Formulary NICE TA385: Ezetimibe for treating primary heterozygous-familial and non-familial hypercholesterolaemia
Febuxostat 10.01.04 Non Formulary NICE TA164: Hyperuricaemia - febuxostat
Febuxostat 10.01.04 Formulary NICE TA164 Dec 2008: Febuxostat for the management of hyperuricaemia in people with gout
Finasteride 06.04.02 Formulary NICE CG97 Lower urinary tract symptoms: quick reference guide
Fingolimod 08.02.04 Formulary NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine Phosphate 08.01.03 Formulary NICE TA29: Leukaemia (lymphocytic) - fludarabine
Fludarabine Phosphate 08.01.03 Formulary NICE TA119: Leukaemia (lymphocytic) - fludarabine
Fludarabine Phosphate 08.01.03 Formulary NICE TA29: Leukaemia (lymphocytic) - fludarabine
Fluocinolone 11.04.01 Formulary NICE TA590: Fluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis
Fluocinolone 11.04.01 Formulary NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy
Fulvestrant 08.03.04.01 Non Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Fulvestrant 08.03.04.01 Non Formulary NICE YA503: Fulvestrant for untreated locally advanced or metastatic oestrogen-receptor positive breast cancer
Gastrocote 08.01 Formulary NICE
Gefitinib 08.01.05 Formulary NICE TA192: Lung cancer (non-small-cell, first line) - gefitinib
Gefitinib 08.01.05 Formulary NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Gemcitabine 08.01.03 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Gemcitabine 08.01.03 Formulary NICE TA116: Breast cancer - gemcitabine
Gemcitabine 08.01.03 Formulary NICE TA25: Pancreatic cancer - gemcitabine
GEMTUZUMAB - OZOGAMICIN Injection 5 mg 20 Non Formulary NICE TA545: Gemtuzumab ozogamicin for untreated acute myeloid leukaemia
Glatiramer Acetate 08.02.04 Formulary NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis
Glecaprevir / Pibrentasvir 05.03.03.02 Formulary NICE TA499: Glecaprevir–pibrentasvir for treating chronic hepatitis C
GLIADEL wafer Carmustine 7.6mg 20 Non Formulary NICE TA121: Glioma - carmustine implants and temozolomide
Golimumab 10.01.03 Non Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Non Formulary NICE TA220: psoriatic arthritis
Golimumab 10.01.03 Non Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Golimumab 10.01.03 Formulary NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Formulary NICE TA375 January 2016: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Golimumab 10.01.03 Formulary NICE TA383 February 2016: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Golimumab 10.01.03 Formulary NICE TA220 April 2011: Golimumab for the treatment of psoriatic arthritis
Golimumab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Guselkumab 13.05.03 Formulary NICE TA521 : Guselkumab for treating moderate to severe plaque psoriasis
Ibrutinib 08.01.05 Formulary NICE TA429 : Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Ibrutinib 08.01.05 Formulary NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Ibuprofen 10.03.02 Formulary Osteoarthritis: care and management
Idelalisib 08.01.05 Formulary NICE TA359: Chronic lymphocytic leukaemia - Idelalisib
Imatinib 08.01.05 Formulary NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Imatinib (Generic) 08.01.05 Formulary NICE TA426 Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Imatinib (Generic) 08.01.05 Formulary NICE TA425 Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Infliximab 01.05.03 Non Formulary NICE TA187: Crohns disease - infliximab & adalimumab
Infliximab 01.05.03 Non Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Infliximab 01.05.03 Non Formulary NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Formulary NICE TA163: Ulcerative colitis (acute manifestations) Infliximab
Infliximab 01.05.03 Formulary NICE TA187: Crohns disease - infliximab & adalimumab
Infliximab 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for moderately to severely active ulcerative colitis
Infliximab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Infliximab 10.01.03 Formulary NICE TA195: Rheumatoid arthritis (after failure of a TNF inhibitor)
Infliximab 10.01.03 Formulary NICE TA199: Psoriatic arthritis
Infliximab 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Infliximab 13.05.03 Formulary NICE TA134: Infliximab for psoriasis
Injection Device 06.01.01.03 Formulary NICE TA442 : Ixekizumab for treating moderate to severe plaque psoriasis
Inotuzumab Ozogamicin 08.01.05 Formulary NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
Interferon Alfa 2a 08.02.04 Formulary NICE TA75: Interferon Alfa - Chronic Hepatitis C
Interferon Beta 08.02.04 Formulary NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon Beta 08.02.04 Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon Beta 08.02.04 Formulary NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon Beta 08.02.04 Formulary NICE TA527 Beta interferons and glatiramer acetate for treating multiple sclerosis
Ipilimumab 08.01.05 Formulary NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ipilimumab 08.01.05 Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Ipilimumab 08.01.05 Formulary NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Ivabradine 02.06.03 Formulary NICE TA267 Nov 2012: Ivabradine for treating chronic heart failure
Ivabradine 02.06.03 Formulary NICE CG126: Guidance on Stable Angina (2011)
Ixekizumab 13.05.02 Formulary NICE TA537: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Ixekizumab 10.01.03 Formulary NICE TA537 August 2018: Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Ixekizumab 13.05.03 Formulary NICE TA442 Ixekizumab for treating moderate to severe plaque psoriasis
Ixekizumab 13.05.03 Formulary NICE TA537 Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs
Lamivudine 05.03.03.01 Formulary NICE CG165: Chronic Hepatitis B
Lansoprazole 01.03.05 Formulary NICE Pathway: Helicobacter pylori testing and eradication in adults
Lapatinib 08.01.05 Non Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Ledipasvir and Sofosbuvir 05.03.03.02 Formulary NICE TAG63: Ledipasvir–sofosbuvir for treating chronic hepatitis C
Ledipasvir and Sofosbuvir 05.03.03.02 Formulary NICE TA430 : Sofosbuvir–velpatasvir for treating chronic hepatitis C
Lenalidomide 08.02.04 Formulary NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least 2 prior therapies
Lenalidomide 08.02.04 Formulary NICE TA 586 Lenalidomide plus dexamethasone for multiple myeloma after 1 treatment with bortezomib
Lenalidomide 08.02.04 Formulary NICE TA587 Lenalidomide plus dexamethasone for previously untreated multiple myeloma
Lenalidomide 08.02.04 Formulary NICE TA 322 Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Lenvatinib 08.01.05 Formulary NICE TA551: Lenvatinib for untreated advanced hepatocellular carcinoma
Lenvatinib 08.01.05 Formulary NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Lenvatinib with Everolimus 08.01.05 Formulary NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Lesinurad 10.01.04 Non Formulary NICE TA506: Lesinurad for treating chronic hyperuricaemia in people with gout
Lisdexamfetamine 16.05 Formulary NICE NG87 Attention deficit hyperactivity disorder: diagnosis and management Sept 2019
Lumacaftor + Ivacaftor 03.07 Non Formulary NICE TA398: Lumacaftor–ivacaftor for treating cystic fibrosis homozygous for the F508del mutation
Lutetium (177Lu) oxodotreotide 08.03.04.03 Formulary NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
Mannitol inhalation 03.07 Formulary NICE TA266: Cystic fibrosis - mannitol dry powder for inhalation
Mepolizumab 03.04.02 Non Formulary NICE TA431 : Mepolizumab for treating severe refractory eosinophilic asthma
Methylphenidate 16.05 Formulary NICE NG87 Attention deficit hyperactivity disorder: diagnosis and management Sept 2019
Methylprednisolone 06.03.02 Formulary NICE CG186: Multiple Sclerosis; management in primary and secondary care.
Methylprednisolone Sodium Succinate 06.03.02 Formulary NICE CG186: Multiple Sclerosis; management in primary and secondary care.
Midostaurin 08.01.05 Formulary NICE TA523: Midostaurin for untreated acute myeloid leukaemia
Mifamurtide 08.02.04 Formulary NICE TA235: Osteosarcoma - mifamurtide: guidance
Milrinone 02.01.02 Non Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Mirabegron 07.04.02 Formulary NICE TA290: Mirabegron for overactive bladder
Naftidrofuryl 02.06.04 Formulary NICE TA223: Intermittent claudication drugs
Naftidrofuryl 02.06.04 Formulary NICE CG147: Lower limb peripheral arterial disease management
Nalmefene 04.10.01 Formulary NICE TA325 Nov 2014: Nalmefene for reducing alcohol consumption in people with alcohol dependence
Naloxegol 01.06.06 Formulary NICE TA345: Naloxegol for treating opioid‑induced constipation
Naltrexone 04.10.03 Formulary NICE TA115: Drug misuse - naltrexone
Naltrexone/ bupropion 04.05.01 Non Formulary Nice TA494: Naltrexone–bupropion for managing overweight and obesity
Natalizumab 08.02.04 Formulary NICE TA127: Multiple sclerosis - natalizumab
Necitumumab 08.01.05 Non Formulary NICE TA411: Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancer
Nilotinib 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Nilotinib 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Nilotinib 08.01.05 Formulary NICE TA251: Dasatinib, nilotinib and imatinib for first line treatment of CML
Nilotinib 08.01.05 Formulary NICE TA241: Dasatinib, nilotinib and high dose imatinib for CML
Nintedanib 03.11 Non Formulary NICE TA347: Recurrent non-small-cell lung cancer
Nintedanib 03.11 Non Formulary NICE TA379:Nintedanib for treating idiopathic pulmonary fibrosis
Nintedanib 08.01.05 Formulary NICE TA347 For treating locally advanced, metastatic or locally recurrant non-small-cell lung cancer
Nivolumab 08.02.04 Formulary NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Nivolumab 08.02.04 Formulary NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Nivolumab 08.02.04 Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Nivolumab 08.02.04 Formulary NICE TA462 : Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Obeticholic acid 01.09.01 Restricted Use NICE TA443: Obeticholic acid for treating primary biliary cholangitis
Obinutuzumab 08.02.03 Formulary NICE TA513:Obinutuzumab for untreated advanced follicular lymphoma
Obinutuzumab 08.02.03 Formulary NICE TA343: Obinutuzumab with chlorambucil for CLL
Ocrelizumab 08.02.03 Formulary NICE TA533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
Ocrelizumab 08.02.03 Formulary NICE TA585: Ocrelizumab for treating primary progressive multiple sclerosis
Ocriplasmin 11.08.02 Non Formulary NICE TA297: Ocriplasmin for treating vitreomacular traction
Ofatumumab 08.02.03 Non Formulary NICE TA344: Ofatumumab with chlorambucil or bendamustine for CLL
Olaparib 08.02.04 Formulary NICE TA381: Olaparib for maintenance treatment of relapsed, platinum-sensitive, BRCA mutation-positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
Omalizumab 03.04.02 Formulary NICE TA278: Omalizumab for treating allergic asthma
Omalizumab 13.05.03 Formulary NICE TA339 Omalizumab for previously treated chronic spontaneous urticaria
Ombitasvir/ paritaprevir/ ritonavir 05.03.03.02 Formulary NICE TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Omeprazole 01.03.05 Formulary NICE Pathway: Helicobacter pylori testing and eradication in adults
Oxaliplatin 08.01.05 Formulary NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Paclitaxel 08.01.05 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Paclitaxel 08.01.05 Formulary NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Paclitaxel 08.01.05 Formulary NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Paclitaxel - Albumin Bound Formulation 08.01.05 Non Formulary NICE TA360: Pancreatic cancer - paclitaxel with gemcitabine
Padeliporfin 08.03.04.02 Non Formulary NICE TA546: Padeliporfin for untreated localised prostate cancer
Palbociclib 08.03.04.01 Non Formulary NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Palbociclib 08.01.05 Formulary NICE TA495 Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic brest cancer
Panitumumab 08.01.05 Formulary NICE TA439 : Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Panobinostat 08.02.04 Formulary NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
Pazopanib 08.01.05 Formulary NICE TA215: Pazopanib in renal cell cancer
Pegaspargase 08.02.04 Formulary NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
Peginterferon Alfa 08.02.04 Formulary NICE TA106: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Alfa 08.02.04 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin & alfa interferon
Peginterferon Alfa 08.02.04 Formulary NICE TA96: Hepatitis B - peginterferon alfa
Peginterferon Alfa 08.02.04 Formulary NICE TA300: Hepatitis C - peginterferon alfa
Peginterferon Alfa 08.02.04 Formulary NICE TA200: Hepatitis C - peginterferon alfa & ribavirin
Peginterferon Beta-1a 08.02.04 Formulary Link NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Pegloticase 20 Non Formulary NICE TA291: Pegloticase not recommended for severe chronic gout
Pembrolizumab 08.01.05 Formulary NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab 08.01.05 Formulary NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pembrolizumab 08.01.05 Formulary NICE TA357: Pembrolizumab for melanoma after ipilimumab
Pembrolizumab 08.01.05 Formulary NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pemetrexed 08.01.03 Formulary NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Pemetrexed 08.01.03 Formulary NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Pemetrexed 08.01.03 Formulary NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
Pemetrexed 08.01.03 Formulary NICE TA135: Mesothelioma - pemetrexed disodium
Penicillamine 10.01.03 Formulary NICE NG100 Rheumatoid arthritis in adults: management July 2018
Perampanel 04.08.01 Formulary NICE CG137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care
Pertuzumab 08.01.05 Formulary NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Pertuzumab 08.01.05 Formulary NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pertuzumab 08.01.05 Formulary NICE TA569: Pertuzumab for adjuvant treatment of HER2-positive early stage breast cancer
Pimecrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Pirfenidone 03.11 Non Formulary NICE TA504: Pirfenidone for treating idiopathic pulmonary fibrosis
Pixantrone 08.01.02 Formulary NICE TA306: Pixantrone monotherapy
Pomalidomide 08.02.04 Formulary NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Pomalidomide 08.02.04 Formulary NICE TA388: Pomalidomide for myeloma
Ponatinib 08.01.05 Formulary NICE TA451 : Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Prasugrel 02.09 Formulary NICE TA317 (replaces TA182): Acute coronary syndrome - prasugrel
Prucalopride 01.06.07 Formulary NICE TA211: Constipation (women) - prucalopride
Radium-223 dichloride 08.03.04.02 Formulary NICE TA412: Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastases
Raloxifene Hydrochloride 06.04.01.01 Formulary Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Ramucirumab 08.01.05 Non Formulary NICE TA403: Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancer
Ranibizumab 11.08.02 Formulary NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
Ranibizumab 11.08.02 Formulary NICE TA298: Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
Ranibizumab 11.08.02 Formulary NICE TA274: Ranibizumab for treating diabetic macular oedema
Ranibizumab 11.08.02 Formulary NICE TA283:Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
Ranolazine 02.06.03 Formulary NICE CG126: Guidance on Stable Angina (2011)
Recombinant human erythropoietins 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Recombinant human erythropoietins 09.01.03 Formulary NICE NG8 June 2015: Chronic kidney disease: managing anaemia
Recombinant human erythropoietins 09.01.03 Formulary NICE TA323: Erythropoiesis‑stimulating agents during chemotherapy
Regorafenib 08.01.05 Formulary NICE TA555: Regorafenib for previously treated advanced hepatocellular carcinoma
Regorafenib 08.01.05 Formulary NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Reslizumab 03.04.02 Non Formulary NICE TA479: Reslizumab for treating severe eosinophilic asthma
Ribavirin 05.03.03.02 Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.03.02 Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.03.02 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribavirin 05.03.05 Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribavirin 05.03.05 Formulary NICE TA300 Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people November 2013
Ribociclib 08.03.04.01 Formulary NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Rifaximin 05.01.07 Formulary NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy (March 2015)
Riluzole 04.09.03 Formulary NICE TA20: Motor neurone disease - riluzole
Risankizumab 13.05.03 Formulary NICE TA596 Risankizumab for treating moderate to severe plaque psoriasis August 2019
Rituximab 08.02.03 Formulary NICE TA174 Rituximab for the first-line treatment of chronic lymphocytic leukaemia
Rituximab 08.02.03 Formulary NICE TA226 Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma
Rituximab 08.02.03 Formulary NICE TA 243 Rituximab for the first-line treatment of stage III-IV follicular lymphoma
Rituximab 08.02.03 Formulary NICE TA193 Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia (TA193)
Rituximab 08.02.03 Formulary NICE TA 137 Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma
Rituximab 10.01.03 Formulary NICE TA195 August 2010: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor
Rituximab 10.01.03 Formulary NICE TA308 March 2014: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Rituximab (rheumatology) 10.01.03 Non Formulary NICE TA195: Rheumatoid arthritis - after failure of a TNF inhibitor
Rivaroxaban 02.08.02 Formulary NICE TA256 May 2012: Rivaroxaban for the prevention of stroke and systemic embolism in people with atrial fibrillation
Rivaroxaban 02.08.02 Formulary NICE TA607 Oct 2019: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
Rivaroxaban 02.08.02 Formulary NICE TA261 July 2012: Rivaroxaban for the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism
Rivaroxaban 02.08.02 Formulary NICE TA287 June 2013: Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism
Rivaroxaban 02.08.02 Formulary NICE TA170 April 2009: Rivaroxaban for the prevention of venous thromboembolism after total hip or total knee replacement in adults
Rivaroxaban 02.08.02 Formulary NICE TA335 March 2015: Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome
Roflumilast 03.03.03 Formulary NICE TA461 : Roflumilast for treating chronic obstructive pulmonary disease
Romiplostim 09.01.04 Formulary NICE TA221: Thrombocytopenic purpura - romiplostim
Ruxolitinib 08.01.05 Formulary NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril valsartan 02.05.05.02 Formulary NICE TA388: Sacubitril valsartan for heart failure (updated 16/7/16 to include adoption resources)
Sarilumab 10.01.03 Formulary NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab 10.01.03 Formulary NICE TA445 May 2017: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Secukinumab 10.01.03 Formulary NICE TA407 September 2017: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Secukinumab 13.05.03 Formulary NICE TA350: Plaque Psoriasis
Simeprevir 05.03.03.02 Formulary NICE TA331: Simeprevir with peginterferon alfa & ribavirin for hepatitis C
Sipuleucel- T 20 Non Formulary NICE TA322: Sipuleucel-T for prostate cancer
Sofosbuvir 05.03.03.02 Formulary NICE TA330: Sofosbuvir for treating chronic hepatitis C
Sofosbuvir/Velpatasvir 05.03.03.02 Formulary NICE TA330: Sofosbuvir for treating chronic hepatitis C
Sofosbuvir/Velpatasvir 05.03.03.02 Formulary Sofosbuvir–velpatasvir for treating chronic hepatitis C
Sofosbuvir+Velpatasvir +Voxilaprevir 05.03.03.02 Formulary NICE TA507: Sofosbuvir–velpatasvir–voxilaprevir for treating chronic hepatitis C
Somatropin 16.11 Formulary Human growth hormone (somatropin) for the treatment of growth failure in children
Somatropin 06.05.01 Formulary NICE TA64: Growth hormone deficiency (adults)
Somatropin 06.05.01 Formulary NICE TA188: Somatropin for growth failure in children
Sorafenib 08.01.05 Formulary NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Sorafenib 08.01.05 Formulary NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Sunitinib 08.01.05 Formulary NICE TA449 : Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Sunitinib 08.01.05 Formulary NICE TA179: Gastrointestinal stromal tumours - sunitinib
Sunitinib 08.01.05 Formulary NICE TA169: Renal cell carcinoma - sunitinib
Tacrolimus 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Tadalafil 07.04.05 Formulary NICE TA273: Hyperplasia (benign prostatic) - tadalafil (terminated appraisal)
Talimogene laherparepvec 08.01.05 Non Formulary NICE TA410: Talimogene laherparepvec for treating unresectable metastatic melanoma
Tegafur with Uracil 08.01.03 Non Formulary NICE TA61: Capcitabine and tegafur - Colorectal cancer
Telaprevir 05.03.03.02 Formulary NICE TA252: Telaprevir in hepatitis C
Temozolomide 08.01.05 Formulary NICE TA121: Glioma (newly diagnosed and high grade)
Temozolomide 08.01.05 Formulary NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
Tenofovir Disproxil 05.03.01 Formulary NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Tenofovir Disproxil 05.03.03.01 Formulary NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Teriflunomide 08.02.04 Formulary NICE TA303: Teriflunomide for relapsing remitting MS
Teriparatide 06.06.01 Formulary NICE TA 161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Thalidomide 08.02.04 Formulary NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Thiamine 09.06.02 Formulary NICE CG100: Management of alcohol-related physical complications
Thiamine 09.06.02 Formulary NICE CG115: Alcohol dependence - diagnosis, assessment and management
Thiamine 09.06.02 Formulary NICE CG115: Alcohol dependence - diagnosis, assessment and management
Thiamine 09.06.02 Formulary NICE CG100: Management of alcohol-related physical complications
Ticagrelor 02.09 Formulary NICE TA236: Ticagrelor for the treatment of acute coronary syndromes
Ticagrelor 02.09 Formulary NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
Tildrakizumab 100mg 13.05.03 Formulary NICE TA575 Tildrakizumab for treating moderate to severe plaque psoriasis April 19
Tivozanib 08.01.05 Formulary Tivozanib for treating advanced renal cell carcinoma
Tivozanib 08.01.05 Formulary NICE TA512: Tivozanib for treating advanced renal cell carcinoma
Tobramycin inhaler 05.01.04 Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Tocilizumab 10.01.03 Formulary NICE TA238 December 2011: Tocilizumab for the treatment of systemic juvenile idiopathic arthritis
Tocilizumab 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Tocilizumab 10.01.03 Formulary NICE TA375: Rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Tocilizumab 10.01.03 Formulary NICE TA518: Tocilizumab for treating giant cell arteritis
Tofacitinib 01.01 Non Formulary NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
Tofacitinib 01.01 Non Formulary NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Tofacitinib citrate 10.01.03 Formulary NICE TA543 October 2018: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Tofacitinib citrate 10.01.03 Formulary NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
Tofacitinib citrate 01.05.03 Formulary NICE TA547: Tofacitinib for moderately to severely active ulcerative colitis
Tolvaptan 06.05.02 Formulary NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan
Tolvaptan 06.05.02 Non Formulary NICE TA358: Autosomal dominant polycystic kidney disease - tolvaptan
Topotecan 08.01.05 Formulary NICE TA184: Lung cancer (small-cell) - topotecan
Topotecan 08.01.05 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Topotecan 08.01.05 Formulary NICE TA183: Cervical cancer (recurrent) - topotecan
Trabectedin 08.01.05 Formulary NICE TA185: Soft tissue sarcoma - trabectedin
Trabectedin 08.01.05 Formulary NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Trametinib 08.01.05 Formulary NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Trametinib 08.01.05 Formulary NICE TA544: Dabrafenib with trametinib for adjuvant treatment of resected BRAF V600 mutation-positive melanoma
Trastuzumab 08.01.05 Formulary NICE TA34: Breast cancer - trastuzumab
Trastuzumab 08.01.05 Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Trastuzumab 08.01.05 Formulary NICE TA208: Gastric cancer (HER2-positive metastatic) - trastuzumab
Trastuzumab emtansine 08.01.05 Formulary NICE TA458 : Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxan
Trifluridine-tipiracil 08.01.05 Formulary NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Trifluridine-tipracil 08.01.03 Non Formulary NICE TA 405 Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Ustekinumab 01.05.03 Formulary NICE TA456 : Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Ustekinumab 10.01.03 Formulary NICE TA340 March 2017 update: Ustekinumab for treating active psoriatic arthritis
Ustekinumab 13.05.03 Formulary NICE TA455 : Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people
Ustekinumab 13.05.03 Formulary NICE TA180: Psoriasis - ustekinumab
Ustekinumab 13.05.03 Formulary NICE TA340: Ustekinumab for treating active psoriatic arthritis
Vandetanib 08.01.05 Non Formulary NICE TA550: Vandetanib for treating medullary thyroid cancer
Varenicline 04.10.02 Formulary NICE TA123: Varenicline
Vedolizumab 01.05.03 Formulary NICE TA352: Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vedolizumab 01.05.03 Formulary NICE TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
Vemurafenib 08.01.05 Formulary NICE TA269: Vemurafenib for treating malignant melanoma
Venetoclax 08.01.05 Formulary NICE TA561: Venetoclax with rituximab for previously treated chronic lymphocytic leukaemia
Verteporfin 11.08.02 Non Formulary NICE TA68: Photodynamic therapy for age related macular degeneration
Vinflunine 08.01.04 Non Formulary NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine
Vismodegib 08.01.05 Non Formulary NICE TA489: Vismodegib for treating basal cell carcinoma
Vortioxetine 04.03.03 Formulary NICE TA367 - Vortioxetine for treating major depressive episodes
Zolpidem 04.01.01 Non Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia
Zopiclone 04.01.01 Formulary NICE TA77: Zaleplon, zolpidem and zopiclone for the management of insomnia